Pharmaceuticals, Biotechnology and Life Sciences
CSL Behring LLC, has gotten the FDA’s approval of Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.
Novo Nordisk got the right from the European Medicines Agency’s committee (EMA) to include data from the LEADER trial to Saxenda to the results from the trial showed the long-term effects of Victoza for type 2 diabetes and established cardiovascular disease patients.
Novartis was cleared on Thursday by the US Food and Drug Administration (FDA) for combination of Tafinlar (dabrafenib) with Mekinist (trametinib) for treating metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express the BRAF V600E mutation, which is fourth actionable genomic biomaker in metastatic NSCLC
Novartis’s Phase III Cantos study of ACZ885 (canakinumab), one of the largest in the company’s history, combined with standard of care in people with a prior heart attack and inflammatory atherosclerosis has met the primary endpoint.
ValiRx’s has formed an Advisory Board to support its main board in new strategic guidance and technical advice.
Herantis Pharma’s clinical study with its investigational gene therapy product Lymfactin for treating secondary lymphedema has advanced to the last patient cohort, owing to good reported safety, the company said Thursday.
Shield Therapeutics’s study suggests that ferric maltol may be effective in patients with active inflammatory markers, and that the ongoing comparative trial of ferric maltol against iv iron will be useful to challenge the prevalent doctrine prohibiting treatment of patients with active systemic inflammation with oral iron.
In a daily briefing, Daily Stock Tracker (DST) gave some insight on certain biotech stocks, noting that companies in this space are almost always unprofitable, and many have no real revenue at all.
Mylan N.V. <MYL.O> is best known for producing EpiPen emergency allergy treatments and generic drugs.
Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.